Fust Matthew K 4
4 · Neumora Therapeutics, Inc. · Filed May 30, 2025
Insider Transaction Report
Form 4
Fust Matthew K
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−27,802→ 0 totalExercise: $1.69Exp: 2033-09-14→ Common Stock (27,802 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+80,000→ 80,000 totalExercise: $0.72Exp: 2035-05-27→ Common Stock (80,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−28,571→ 0 totalExercise: $1.69Exp: 2034-06-13→ Common Stock (28,571 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-05-28−85,586→ 0 totalExercise: $1.69Exp: 2031-04-23→ Common Stock (85,586 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+28,571→ 28,571 totalExercise: $0.72Exp: 2034-06-13→ Common Stock (28,571 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+85,586→ 85,586 totalExercise: $0.72Exp: 2031-04-23→ Common Stock (85,586 underlying) - Award
Stock Option (Right to Buy)
2025-05-28+27,802→ 27,802 totalExercise: $0.72Exp: 2033-09-14→ Common Stock (27,802 underlying)
Footnotes (5)
- [F1]The stock option is fully vested and exercisable.
- [F2]On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
- [F3]100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.
- [F4]On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
- [F5]100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025.